Avacta Therapeutics has reported outcomes from the Phase Ia trial of AVA6000, a drug candidate for solid tumours.

Au21m grading 1.29g/t Au4m grading 5.04g/t AuVANCOUVER, British Columbia, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Winshear Gold ...

It’s that time of year when Americans who made New Year’s resolutions come face-to-face with what has become known as ...

Everand, a Scribd, Inc. company and the leading destination for millions of ebooks, audiobooks, and more, today released its first State of Reading Re ...